Malignant glioma drug discovery - Targeting protein kinases

Expert Opinion on Drug Discovery

Volumn 2, Issue 1, 2007, Pages 1-17

  Sathornsumetee, Sith ^a   Vredenburgh, Kaitlyn A ^a   Lattimore, Kathryn P ^a   Rich, Jeremy N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioblastoma; Glioma; Protein kinase; Serine threonine; Signal transduction; Targeted therapy; Tyrosine

Indexed keywords

AAL 881; ANTINEOPLASTIC AGENT; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HKI 272; HYDROXYUREA; IMATINIB; LOMUSTINE; LONAFARNIB; PELITINIB; PERIFOSINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; RAS PROTEIN; SCATTER FACTOR; SOMATOMEDIN RECEPTOR; SORAFENIB; TEMOZOLOMIDE; TIPIFARNIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CARCINOGENESIS; CHROMOSOME 7; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 34447510953     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.1.1     Document Type: Review

References (149)

1. CENTRAL BRAIN TUMOR REGISTRY OF THE UNITED STATES: Statistical report: Primary Brain Tumors in the United States, 1997-2001. Central brain tumor registry of the United States (CBTRUS), IL, USA (2005).
2. KLEIHUES P, CAVENEE WK: World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System, (2nd edn), WHO Publications Centre USA, Albany, 2000.
3. DEANGELIS LM: Brain tumors. N. Engl. J. Med. (2001) 344:1140-123.
4. LACROIX M, ABI-SAID D, FOURNEY DR et al.: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. (2001) 95(2):190-198.
5. STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
6. TAPHOORN MJ, STUPP R, COENS C et al.: Health-related quality of life in patients with glioblasmma: a randomized controlled trial. Lancet Oncol. (2005) 6(12):937-944.
7. SCOTT CB, SCARANTINO C, URTASUN R et al.: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int. J. Radiat. Oncol. Biol. Phys. (1998) 40:51-55.
8. WONG ET, HESS KR, GLEASON MJ et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trial. J. Clin. Oncol. (1999) 17:2572-2578.
9. HANAHAN D, WEINBERG R: The hallmarks of cancer. Cell (2000) 100:57-70.
10. SMITH JS, TACHIBANA I, PASSE SM et al.: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblasmma multiforme. J. Natl. Cancer Inst. (2001) 93(16):1246-1256.
11. DAI C, CELESTINO JC, OKADA Y, LOUIS DN, FULLER GN, HOLLAND EC: PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. (2001) 15(15):1913-1925.
12. ROWINSKY, ERIC K: Signal events: cell signal transduction and its inhibition in cancer. Oncologist (2003) 8(Suppl. 3):5-17.
13. FELDKAMP MM, LAU N, GUHA A: Signal transduction pathways and their relevance in human astrocytomas. J. Neurooncol. (1997) 35(3):228-248.
14. BLUME-JENSEN P, HUNTER T: Oncogenic kinase signaling. Nature (2001) 411:355-365.
15. COHEN P: Protein kinases, the major drug targets of the 21st century? Nat. Rev. Drug Discov. (2002) 1:309-316.
16. FUTREAL P, KASPRZYK A, BIRNEY E et al.: Cancer and genomics. Nature (2001) 409:850-852.
17. FABBRO D, RUETZ S, BUCHDUNGER E et al.: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. (2002) 93:79-98.
18. ROBINSON DR, WU YM, LIN SF: The protein tyrosine kinase family of the human genome. Oncogene. (2000) 19(49):5548-5557.
19. SATHORNSUMETEE S, RICH JN: New treatment strategies for malignant gliomas. Expert Rev. Anti-Cancer Ther. (2006) 6(7):1-18.
20. CITRI A, YARDEN Y: EGF-ERBB signaling: towards the systems level. Nat. Rev. Mol. Cell Biol. (2006) 7(7):505-516.
21. CHU CT, EVERISS KD, WIKSTRAND CH et al.: Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. (1997) 324(Pt 3):855-861.
22. ARTEAGA CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human meoplasia. J. Clin. Oncol. (2001) 19:325-405.
23. RICH JN, REARDON DA, PEERY T et al.: Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. (2004) 22(1):133-142.
24. GALANIS E, BUCKNER JC, MAURER MJ et al.: Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro-oncol. (2006) 8(2):156-165.
25. PRADOS MD, LAMBORN KR, CHANG S et al.: Phase I study of erlotinib HCI alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neurooncol. (2006) 8:67-78.
26. VOGELBAUM MA, PEEREBOOM D, STEVENS G, BARNETT G, BREWER C: Phase II trial of EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc. Am. Soc. Clin. Oncol. (2004) 22:1558a.
27. RAIZER JJ, ABREY LE, WEN P et al.: Phase II trial of erlotinib (OSI-779) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc. Am. Soc. Clin. Oncol. (2004) 22:1502a.
28. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350(21):2129-2139.
29. RICH JN, RASHEED BK, YAN H: EGFR mutations and sensitivity to gefitinib. N. Engl. J. Med. (2004) 351(12):1260-1261.
30. LASSMAN AB, ROSSI MR, RAIZER JJ et al.: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res. (2005) 11(21):7841-7850.
31. MARIE Y, CARPENTIER AF, OMURO AM et al.: EGFR tyrosine kinase domain mutations in human gliomas. Neurology (2005) 64(8):1444-1445.
32. HAAS-KOGAN DA, PRADOS MD, TIHAN T et al.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. (2005) 97:880-887.
33. MELLINGHOFF IK, WANG MY, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353:2012-2014.
34. ELLER JL, LONGO SL, HICKLIN DJ, CANUTE GW: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. (2002) 51(4):1005-1013.
35. ELLER JL, LONGO SL, KYLE MM, BASSANO D, HICKLIN DJ, CANUTE GW: Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery (2005) 56(1):155-162.
36. SADONES J, CHASKIS E, JOOSENS EJ et al.: A stratified Phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. Proc. Am. Soc. Clin. Oncol. (2006) 24:18S. Abstract 1558.
37. JI H, ZHAO X, YUZA Y et al.: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA (2006) 103(20):7817-7822.
38. ERLICHMAN C, HIDALGO M, BONI JP et al.: Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. (2006) 24(15):2252-2260.
39. SHIH AH, HOLLAND EC: Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. (2006) 232(2):139-147.
40. BUCGDUNGER E, CIOFFI CL, LAW N et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. (2000) 295(1):139-145.
41. SERVEDEI T, RICCARDI A, SANGUINETTI M et al.: Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J. Cell Phys. (2006) 208:220-228.
42. KILIC T, ALBERTA JA, ZDUNEK PR et al.: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenlaminopyrimidine class. Cancer Res. (2000) 60(18):5143-5150.
43. GENG L, SHINOHARA ET, KIM D et al.: STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int. J. Radiat. Oncot Biol. Phys. (2006) 64(1):263-271.
44. WEN PY, YUNG WK, LAMBORN KR et al.: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. (2006) 12(16):4899-4907.
45. DRESEMANN G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol. (2005) 16(10):1702-1708.
46. REARDON DA, EGORIN MJ, QUINN JA et al.: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. (2005) 23(26):9359-9368.
47. PIETRAS K, OSTMAN A, SJOQUIST M et al.: Inhibition of platelet-derived growth factor receptors reduced interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. (2005) 61(7):2577-2582.
48. BIHORELS, CAMENISCH G, GROSS G, LEMAIRE M, SCHERRMANN JM: Influence of hydroxyurea on imatinib mesylate transport at the mouse blood-brain barrier. Drug Metab. Dispos. (2006) Epub ahead of print.
49. SATHORNSUMETEE S, REARDON DA, QUINN JA et al.: An update on Phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):1560.
50. VAJKOCZY P, THURNHER A, HIRTH KP et al.: Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications. Oncologist (2000) 5:16-19.
51. GOLDBRUNNER RH, BENDSZUS M, WOOD J, KIDERLEN M, SASAKI M, TONN JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery (2004) 55(2):426-432.
52. FOLKMANN J: What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. (1990) 82:4-6.
53. CONRAD C, FRIEDMAN H, REARDON D et al.: A Phase I/II trial of single-agent PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) 22(110S):1512.
54. REARDON D, FRIEDMAN H, YUNG WKA et al.: A Phase I/II trial of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) 22(110S):1513.
55. BASERGA R: The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin. Ther. Targets (2005) 9(4):753-768.
56. CHAKRAVARTI A, LOEFFLER JS, DYSON NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. (2002) 62(1):200-207.
57. WANG Y, HAILEY J, WILLIAMS D et al.: Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. (2005) 4(8):1214-1221.
58. KOOCHEKPOURS, JEFFERS M, RULONG S et al.: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. (1997) 57(23):5391-5398.
59. ABOUNADER R, RANGANATHAN S, LAL B et al.: Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. (1999) 91(18):1548-1556.
60. LAL B, XIA S, ABOUNADER R, LATERRA J: Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin. Cancer Res. (2005) 11(12):4479-4486.
61. CAOB, SU Y, OSKARSSON M et al.: Neutralizing monoclonal antibodies to heparocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA (2001) 98(13):7443-7448.
62. BURGESS T, COXON A, MEYER S et al.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. (2006) 66(3):1721-1729.
63. MARTENS T, SCHMIDT NO, ECKERICH C et al.: A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. (2006) 12(20):6144-6152.
64. ADJEI AA, HIDALGO M: Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. (2005) 23(23):5386-5403.
65. MARTIN GS: The road to Src. Oncogene (2004) 23:7910-7917.
66. LUND CV, NGUYEN MT, OWENS GC et al.: Reduced glioma infiltration in Src-deficient mice. J. Neurooncol. (2006) 78(1):19-29.
67. RICH JN, HANS C, JONES B et al.: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. (2005) 65:4051-4058.
68. TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354(24):2531-2541.
69. GUTENBERG A, BRUCK W, BUCHFELDER M, LUDWIG HC: Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta Neuropathol. (Berl). (2004) 108(3):224-230.
70. HASKELL H, NATARAJAN M, HECKER TP et al.: Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin. Cancer Res. (2003) 9(6):2157-2165.
71. SHI Q, HJELMELAND AB, KEIR ST et al.: TAE226, a novel low-molecular weight inhibitor of focal adhesion kinase, inhibits glioma growth. Neuro-Oncol. (2006) 8(4):417 (Abstract ET-34).
72. KNOBBE CB, REIFENBERGER J, REIFENBERGER G: Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. (Berl). (2004) 108(6):467-470.
73. PARSA AT, HOLLAND EC: Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol. Med. (2004) 10(12):607-613.
74. SEBOLT-LEOPOLD JS, HERRERA R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer (2004) 4(12):937-947.
75. CARAGLIA M, TASSONE P, MARRA M, BUDILLON A, VENUTA S, TAGLIAFERRI P: Targeting Raf-kinase: molecular rationales and translational issues. Ann. Oncol. (2006) 17(Suppl. 7):vii124-vii127.
76. ROUX PP, BLENIS J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological function. Mircobiol. Mol. Biol. Rev. (2004) 68(2):320-344.
77. APPELS NM, BEIJNEN JH, SCHELLENS JH: Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 10(8):565-578.
78. CLOUGHESY TF, KUHN J, ROBINS HI et al.: Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol. (2005) 23(27):6647-6656.
79. CLOUGHESY TF, WEN PY, ROBINS HI et al.: Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol. (2006) 24(22):3651-3656.
80. SATHORNSUMETEE S, HJELMELAND AB, KEIR ST et al.: AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks growth of malignant glioma. Cancer Res. (2006) 66(17):8722-8730.
81. NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anti-Cancer Ther. (2004) 4(1): 105-128.
82. BADER AG, KANG S, ZHAO L, VOGT PK: Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer (2005) 5(12):921-929.
83. CHAKRAVARTI A, ZHAI G, SUZUKI Y et al.: The prognostic significance of phospharidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. (2004) 22(10):1926-1933.
84. HAAS-KOGAN D, SHALEV N, WONG M, MILLS G, YOUNT G, STOKOE D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. (1998) 8(21):1195-1198.
85. 2/M cell cycle checkpoint induced by DNA damage. Mol. Cell. Biol. (2002) 22(22):7831-7841.
86. SHAW RJ, CANTLEY LC: Ras, PI(3)K, and mTOR signalling controls tumor cell growth. Nature (2006) 441:424-430.
87. MITA MM, MITA A, ROWINSKY EK et al.: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. (2003) 2(4 Suppl. 1):S169-S177.
88. MOMOTA H, NERIO E, HOLLAND EC: Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. (2005) 65(16):7429-7435.
89. GALANIS E, BUCKNER JC, MAURER MJ et al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Carolina Cancer Treatment Group Study. J. Clin. Oncol. (2005) 23(23):5294-5304.
90. CHANG SM, WEN P, CLOUGHESY T et al.: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs (2005) 23(4):357-361.
91. IWAMARU A, KONDO Y, IWADO E et al.: Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene (2006) Epub ahead of print.
92. THOMAS GV, TRAN C, MELLINGHOFF IK et al.: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. (2006) 12(1):122-127.
93. OKHRIMENKO H, LU W, XIANG C, HAMBURGER N, KAZIMIRSKY G, BRODIE C: Protein kinase C-ε regulates the apoptosis and survival of glioma cells. Cancer Res. (2005) 65(16):7301-7309.
94. DA ROCHA AB, MANS DR, REGNER A, SCHWARTSMANN G: Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist (2002) 7(1):17-33.
95. NISHIZUKA Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (1988) 334(6184):661-665.
96. GRAFF JR, MCNULTY AM, HANNA KR et al.: The protein kinase Cβ-selective inhibitor, enzastaurin (LY317613.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. (2005) 65(16):7462-7469.
97. HUI AM, ZHANG W, CHEN W et al.: Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. (2004) 64(24):9115-9123.
98. CHAMBERLAIN MC, KORMANIK PA: Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch. Neurol. (1999) 56(6):703-708.
99. BRANDES AA, ERMANI M, TURAZZI S et al.: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a Phase II study. J. Clin. Oncol. (1999) 17(2):645-650.
100. SPENCE AM, PETERSON RA, SCHARNHORST JD, SILBERGELD DL, ROSTOMILY RC: Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMZ) for recurrent malignant astrocytic gliomas. J. Neurooncol. (2004) 70(1):91-95.
101. FINE HA, KIM L, ROYCE C et al.: Results from Phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc. Am. Soc. Clin. Oncol. (2005) 23(Suppl. 115S):1504.
102. DRUKER B, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
103. RICH JN, SATHORNSUMETEE S, KEIR ST et al.: ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res. (2005) 11(22):8145-8157.
104. SCHUENEMAN AJ, HIMMELFARB E, GENG L et al.: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. (2003) 63(14):4009-4016.
105. FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24(1):25-35.
106. BURRIS HA III, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23(23):5305-5313.
107. JONES-BOLIN S, ZHAO H, HUNTER K, KLEIN-SZANTO A, RUGGERI B: The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther. (2006) 5(7):1744-1753.
108. POLVERINO A, COXON A, STARNES C et al.: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. (2006) 66(17):8715-8721.
109. ALBERT DH, TAPANG P, MAGOC TJ et al.: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. (2006) 5(4):995-1006.
110. FAN QW, KNIGHT ZA, GOLDENBERG DD et al.: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. (2006) 9(5):341-349.
111. LI B, CHANG CM, YUAN M, MCKENNA WG, SHU HK: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. (2003) 63(21):7443-7450.
112. O'REILLY KE, ROJO F, SHE QB et al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. (2006) 66(3): 1500-1508.
113. HUANG S, ARMSTRONG EA, BENAVENTE S, CHINNAIVAN P, HARARI PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. (2004) 64(15):5355-5362.
114. GOUDAR RK, SHI Q, HJELMELAND MD et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2(AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. (2005) 4(1):101-112.
115. RAO RD, MLADEK AC, LAMONT JD et al.: Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia (2005) 7(10):921-929.
116. WANG MY, LU KV,, ZHU S et al.: Mammalian target of rapamycin Inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. (2006) 66(16):7864-7869.
117. REARDON DA, QUINN JA, VREDENBURGH JJ et al.: Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. (2006) 12(3 Pt 1):860-868.
118. DOHERTY L, GIGAS DC, KESARI S et al.: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology (2006) 67(1):156-158.
119. EDWARDS LA, VERREAULT M, THIESSEN B et al.: Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol. Cancer Ther. (2006) 5(3):645-654.
120. JANE EP, PREMKUMAR DR, POLLACK IF: Coadministrafion of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J. Pharmacol. Exp. Ther. (2006) Epub ahead of print.
121. YU C, FRIDAY BB, LAI JP et al.: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. (2006) 5(9):2378-2387.
122. MANIA, GELMANN EP: The ubiquitin-proteasome pathway and its role in cancer. J. Clin Oncol. (2005) 23:4776-4789.
123. PHUPHANICH S, SUPKO J, CARSON KA et al.: Phase I trial of bortezomib in adults with malignant glioma. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):1567.
124. PREMKUMAR DR, ARNOLD B, JANE EP, POLLACK IF: Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol. Carcinog. (2006) 45(1):47-59.
125. RICHTER K, BUCKNER J: Hsp90: chaperoning signal transduction. J. Cell. Physiol. (2001) 188:281-290.
126. PRADOS M, YUNG W, WEN P et al.: Phase I study of ZD 1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proc. Am. Soc. Clin. Oncol. (2004) 22(14):1504.
127. DAMIANO V, MELISI D, BIANCO C et al.: Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin. Cancer Res. (2005) 11(15):5639-5644.
128. SARKARIA JN, CARLSON BL, SCHROEDER MA et al.: Use of an orthoropic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res.. (2006) 12(7 Pt 1):2264-2271.
129. KRISHNAN S, BROWN PD, BALLMAN KY et al.: Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int. J. Radiat. Oncol. Biol. Phys. (2006) 65(4):1192-1199.
130. VREDENBURGH J, DESJARDINS A, HERNDON JE et al.: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S): 1506.
131. IMAI K, TAKAOKA A: Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer (2006) 6:717-727.
132. HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21(23):4342-4349.
133. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
134. DRUKER BJ: Circumventing resistance to kinase-inhibitor therapy. N. Engl. J. Med. (2006) 354(24):2594-2596.
135. KANTARJIAN H, GILES F, WUNDERLE L et al.: Nilotinib in imatinib-tesistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354(24):2542-2551.
136. DANCEY JE, CHEN HX: Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. (2006) 5:649-659.
137. BILD AH, POTTI A, NEVINS JR: Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer (2006) 6(9):735-741.
138. HATANO M, EGUCHI J, TATSUMI T et al.: EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (2005) 7(8):717-722.
139. NAKADA M, DRAKE KL, NAKADA S, NISKA JA, BEREN ME: Ephrin-B3 ligand promotes glioma invasion through activation of Racl. Cancer Res. (2006) 66(17):8492-500.
140. LIPINSKI CA, TRAN NL, MENASHI E et al.: The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia (2005) 7(5):435-445.
141. HJELMELAND MD, HJELMELAND AB, SATHORNSUMETEE S et al.: SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. (2004) 3(6):737-745.
142. UHL M, AULWURM S, WISCHHUSEN J et al.: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. (2004) 64(21):7954-7961.
143. DIETZMANN K, KIRCHES E, VON BOSSANYI, JACHAU K, MAWRIN C: Increased human polo-like kinase-1 expression in gliomas. J. Neurooncol. (2001) 53(1):1-11.
144. NEWCOMB EW, ALI MA, SCHNEE T et al.: Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-oncol. (2005) 7(3):225-235.
145. LASSMAN AB, ABREY LE, GILBERT MR: Response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2006) 354(5):525-526.
146. WEN PY, KESARI S, DRAPPATZ J: Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev. Anti-Cancer Ther. (2006) 6(5):733-754.
147. BREEDVELD P, PLUIM D, CIPRIANI G et al.: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. (2005) 65(7):2577-2582.
148. JAIN RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 307(5706):58-62.
149. KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.